MedPath

湖北汇中制药股份有限公司

Ownership
-
Established
2003-10-31
Employees
-
Market Cap
-
Website
http://www.hbhzzy.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

23

NMPA:23

Drug Approvals

众生胶囊

Approval Number
国药准字Z20080483
Approval Date
May 10, 2023
NMPA

Montmorillonite Powder

Product Name
蒙脱石散
Approval Number
国药准字H20067391
Approval Date
Aug 3, 2021
NMPA

复方丹参片

Approval Number
国药准字Z42020628
Approval Date
Sep 4, 2020
NMPA

Inosine Tablets

Product Name
肌苷片
Approval Number
国药准字H42020555
Approval Date
Sep 4, 2020
NMPA

Chloramphenicol Tablets

Product Name
氯霉素片
Approval Number
国药准字H42020549
Approval Date
Sep 4, 2020
NMPA

Metamizole Sodium Tablets

Product Name
安乃近片
Approval Number
国药准字H42020553
Approval Date
Sep 4, 2020
NMPA

Oyster Shell Calcium Oranules

Product Name
牡蛎碳酸钙颗粒
Approval Number
国药准字H42022415
Approval Date
Sep 4, 2020
NMPA

Glucurolactone Tablets

Product Name
葡醛内酯片
Approval Number
国药准字H42020558
Approval Date
Sep 4, 2020
NMPA

Compound Sulfamethoxazole Tablets

Product Name
复方磺胺甲噁唑片
Approval Number
国药准字H42020552
Approval Date
Sep 4, 2020
NMPA

Rifampicin Capsules

Product Name
利福平胶囊
Approval Number
国药准字H42020550
Approval Date
Sep 4, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.